A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Pemetrexed
- Indications Head and neck cancer; Non-small cell lung cancer; Oropharyngeal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Acronyms CLOVER
- Sponsors AstraZeneca
- 02 Aug 2019 Planned number of patients changed from 300 to 360.
- 08 May 2018 Planned End Date changed from 31 Mar 2022 to 4 Apr 2022.
- 08 May 2018 Planned primary completion date changed from 31 Mar 2022 to 4 Apr 2022.